期刊
ADVANCES IN THERAPY
卷 36, 期 4, 页码 870-879出版社
SPRINGER
DOI: 10.1007/s12325-019-00910-z
关键词
B cell precursor acute lymphoblastic leukemia; Cure; Outcomes; Oncology; Refractory ALL; Relapsed ALL; Survival
资金
- Amgen Inc.
Introduction: Despite the poor prognosis for adults with relapsed or refractory (RR) Philadelphia chromosome (Ph)-negative Bcell precursor acute lymphoblastic leukemia (ALL), long-term survival is possible and may even be considered as cure. Methods: This study used a Delphi panel approach to explore concepts of cure in RR Ph-negative Bcell precursor ALL. Ten European experts in this disease area participated in a survey and face-to-face panel meeting. Results: Findings showed that clinicians conceptualize cure as a combination of three broad treatment outcomes that vary depending on the treatment stage: complete remission early in treatment (1-3 months) indicates initial success; eradicating cancer cells (minimal residual disease negative status) consolidates the early clinical response; leukemia-free survival is required in the long term. Conclusions: Although such terminology remains contested, clinicians would begin considering cure as early as 2 years provided the patient is off therapy, with most considering the term applicable by the third year.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据